Healthcare and Biotech
Conference Explores Innovations to Transform Health Across the Globe
A new generation of medical "rock stars" are blending cutting-edge technology with reams of old-fashioned data to help drive innovation, said Todd Park, chief technology officer of the U.S. Department of Health and Human Services, and one of the participants in the 2001 Healthcare Summit held at the Stanford Graduate School of Business.
"DC2VC" Event Connects Student Entrepreneurs with Government Representatives and Investors
Six teams of graduate student entrepreneurs spent a lunch hour with a panel of government representatives and investors describing their ideas and the barriers preventing them from bringing their cost-saving health care innovations to market.
Conference Highlights Operations Research
Researchers exploring problems such as security, energy and environment, critical infrastructure, and health care, came together at a conference at the Stanford Graduate School of Business on Operations Research for the Public Interest. Most of the papers presented were written by collaborative teams of academics working with experts from government, non-governmental organizations, and international development organization.
Effectiveness Research Could Pose Barriers to Medical Development
The United States' commitment to comparative effectiveness research for medical treatments could hamper young companies and delay some products, but it also could create more value for successful early-stage companies, agreed speakers at a roundtable on biodesign held at the Stanford Graduate School of Business.
Diagnostic Test Technology Will Change Medical Treatment
Of the $2.2 trillion spent on U.S. health care in 2008, diagnostic tests accounted for just 2 percent of total dollars spent. Yet the results of such tests drive 70 percent of treatment decisions, speakers told the Healthcare Summit at the Stanford Graduate School of Business.
Biotech Startups Face New Challenges in the Marketplace
Venture capitalists ask tougher questions and increasingly biotechstartups are facing competition from mainstream drug companies, but thereare still plenty of opportunities, speakers told the annual Stanford GraduateSchool of Business Health Care Symposium.
Reinventing Health Care, Drug Development, and the FDA
America's health care system is broken, drug development takes too long and costs too much, and the FDA needs major reform,speakers told the annual Health Care and Biotech Symposium. (March 2005)
Shortages of Health Services, Abundance of Red Tape Hamper AIDS/HIV Battle
Understaffed and inadequate internal health-care systems andred tape are major roadblocks to fighting the spread of AIDS/HIVin developing countries, speakers told a conference on internationaldevelopment. (February 2005)
Keynote Address
Debrework Zewdie
Director, Global HIV/AIDS Program, World BankPanel on Delivery Innovations
Judith Justice, Moderator
Associate Professor, University of California, San FranciscoOphelia Dahl
President and Executive Director, Partners in HealthJack Higgins
Digital Vision Fellow, Global Telemedicine ProjectVikram Kumar
Director, Dimagi, Inc.Tony Carroll
Consultant, Merck and Co.Panel on Funding Innovations
Donovan Cook, Moderator
Western Region Director of Development, Save the Children, PaloAlto, Calif.Timothy Goodman
Assistant Director for Global Policy, Pfizer Inc.Srividya Prakash
Global Health Group, McKinsey & Co., San FranciscoDavid Green
CEO, Project Impact, Berkeley, Calif.Panel on Medical Innovations
Vera Kulmyer, Moderator
Consulting Professor, Stanford Medical SchoolDepartment of Neurosurgery; Founder and Managing Partner, Equity for HealthDouglas Holtzman
Program officer for Infectious Diseases, Bill and Melinda GatesFoundationGeorge Rutherford
Interim Director, UCSF Institute for Global HealthKatherine Woo
Director of Scientific Affairs, One World HealthNzeera Ketter
Director, Efficacy Trials, International AIDS Vaccine Initiative
Reinventing Health Care, Drug Development, and the FDA
America's health care system is broken, drug development takes too long and costs too much, and the FDA needs major reform,speakers told the annual Health Care and Biotech Symposium.
2004
Offshore Drug Development May Be Necessary to Control Cost
Doing at least preclinical drug development outside the United States may be necessary to bring down costs, speakers told the annual Health Care and Biotech Symposium. (March 2004)
2003
Conference Highlights Critical Role of Consumer Choice in Health-Related Businesses
Advances in health care are giving people longer and healthier lives, butthe 40 million Americans not covered by any type of insurance are makingit increasingly difficult to pay the bills and support the research,agreed speakers at the Stanford Graduate School of Business' fourthannual health care and biotech conference. (January 2003)
2002
Biotech Innovators and Investors Assess Challenges, Opportunities
The biotechnology industry faces major productivity challenges on the road to profits, but venture capitalists predict blue skies ahead—with just a few dark clouds. (February 2002)
2001
Genomics Industry Follows a Bumpy Road
The science of genomics is rapidly changing two business sectors—capital and pharmaceuticals—leaders in those industries said speakers at the Health Care Conference. (January 2001)
2000
The Internet May Transform Health Care
E-commerce and genomics will radically transform the stodgy pharmaceutical and health-care industries, according to industry leaders at the Stanford Business School's first Health Care and Technology conference.
Genome Research Is Changing Pharmaceuticals
The Human Genome Project will spur the development of several new types of businesses, according to the panelists at a biotechnology discussion at Stanford Business School's Health Care Technology Conference.